ArticleJAMA oncology2019
PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: Understanding the Upside of the Downside of Checkpoint Blockade.
Diwakar Davar et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
19 papers cite it
this paperpooled ittrialcites it